Jack W Callicutt sold $479k of GALT
Chief Financial Officer at GALECTIN THERAPEUTICS INC. 77,920 shares at an average of $6.15, traded Nov 17, 2025, filed Nov 19, 2025.
Score components
- +22RoleCFO
- +18Trade size$479k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -23.7%, 3m -50.9%, 6m -61.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001133416-25-000057, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | MOption exercise Common stock10b5-1 | +9,586 | $1.98 | $19k | 17,200 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common stock10b5-1 | -9,586 | $6.03 | $58k | 7,614 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Common stock10b5-1 | +19,701 | $1.11 | $22k | 27,315 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common stock10b5-1 | -19,701 | $6.03 | $119k | 7,614 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Common stock10b5-1 | +2,323 | $1.23 | $2,857 | 9,937 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common stock10b5-1 | -2,323 | $6.03 | $14k | 7,614 | Nov 19, 2025 |
| Nov 18, 2025 | MOption exercise Common stock10b5-1 | +28,100 | $1.98 | $56k | 35,714 | Nov 19, 2025 |
| Nov 18, 2025 | SOpen-market sale Common stock10b5-1 | -28,100 | $6.22 | $175k | 7,614 | Nov 19, 2025 |
| Nov 18, 2025 | MOption exercise Common stock10b5-1 | +18,210 | $1.11 | $20k | 25,824 | Nov 19, 2025 |
| Nov 18, 2025 | SOpen-market sale Common stock10b5-1 | -18,210 | $6.22 | $113k | 7,614 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Stock option (right to buy)derivative10b5-1 | -9,586 | $0.00 | $0 | 28,120 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Stock option (right to buy)derivative10b5-1 | -19,701 | $0.00 | $0 | 18,190 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Stock option (right to buy)derivative10b5-1 | -2,323 | $0.00 | $0 | 48,750 | Nov 19, 2025 |
| Nov 18, 2025 | MOption exercise Stock option (right to buy)derivative10b5-1 | -28,120 | $0.00 | $0 | 0 | Nov 19, 2025 |
| Nov 18, 2025 | MOption exercise Common stock (right to buy)derivative10b5-1 | -18,190 | $0.00 | $0 | 0 | Nov 19, 2025 |
Related signals
Other insiders at GALECTIN THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 9Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $83k 16,250 shares | -100% | |
| 21Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $262k 52,037 shares | -2555% | |
| 19Weak | GALECTIN THERAPEUTICS INC | Harold H. Shlevin director | $151k 30,000 shares | -211% | |
| 8Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $24k 7,557 shares | -100% | |
| 0Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $1,761 568 shares | -100% | |
| 23Weak | GALTbuy GALECTIN THERAPEUTICS INC | Kary Eldred director | $810 300 shares | +0% | |
| 35Weak | GALECTIN THERAPEUTICS INC | Jack W Callicutt Chief Financial Officer | $233k 60,000 shares | -89% | |
| 28Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $232k 60,000 shares | -100% | |
| 19Weak | GALECTIN THERAPEUTICS INC | Joel Lewis President and CEO | $321k 84,000 shares | -9% | |
| 21Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $33k 8,125 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.